Patents Examined by Dameron Jones
  • Patent number: 7229604
    Abstract: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.
    Type: Grant
    Filed: September 26, 2003
    Date of Patent: June 12, 2007
    Assignee: Board of Regents, The University of Texas System
    Inventors: David J. Yang, Chun W. Liu, Dong-Fang Yu, E. Edmund Kim
  • Patent number: 7097826
    Abstract: A compound comprising a chemical combination of a photodynamic tetra-pyrrolic compound with a plurality of radionuclide element atoms such that the compound may be used to enhance MR imaging and also be used as a photodynamic compound for use in photodynamic therapy to treat hyperproliferative tissue. The preferred compounds have the structural formula: where R1, R2, R2a R3, R3a R4, R5, R5a R6, R7, R7a, and R8 cumulatively contain at least two functional groups that will complex or combine with an MR imaging enhancing element or ion. The compound is intended to include such complexes and combinations and includes the use of such compounds for MR imaging and photodynamic therapy treatment of tumors and other hyperproliferative tissue.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: August 29, 2006
    Assignee: Health Research, Inc.
    Inventors: Ravindra K. Pandey, Zachary Grossman, Peter Kanter, Thomas J. Dougherty
  • Patent number: 7060248
    Abstract: Thus the present invention describes diagnostic agents comprising a diagnostic metal and a compound, wherein the compound comprises: 1-10 targeting moieties; a chelator; and 0-1 linking groups between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to the diagnostic metal. The present invention also provides novel compositions of the compounds of the invention, kits, and their uses in diagnosis of diseases associated with MMPs.
    Type: Grant
    Filed: August 21, 2003
    Date of Patent: June 13, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Alan P. Carpenter, Jr., Milind Rajopadhye
  • Patent number: 7060251
    Abstract: The invention provides imaging agents comprising a label in association with a plaque specific targeting molecule. Methods for using the imaging agents to diagnose or monitor plaque formation and growth and kits containing the cardiovascular agents or components suitable for production of the imaging agents are also provided.
    Type: Grant
    Filed: September 8, 1998
    Date of Patent: June 13, 2006
    Assignee: The General Hospital Corporation
    Inventors: David R. Elmaleh, Alan J. Fischman, John W. Babich
  • Patent number: 7018611
    Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.
    Type: Grant
    Filed: October 26, 2002
    Date of Patent: March 28, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Thomas D. Harris, John A. Barrett, Alan P. Carpenter, Jr., Milind Rajopadhye
  • Patent number: 6936700
    Abstract: The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: August 30, 2005
    Assignee: NeoRx Corporation
    Inventor: Sudhakar Kasina
  • Patent number: 6921525
    Abstract: The invention provides a composition of matter of the formula (I): V-L-R where V is an organic group having binding affinity for an angiotensin II receptor site, L is a linker moiety or a bond, and R is a moiety detectable in in vivo imaging of a human or animal body, with the provisos that where V is angiotensin or a peptidic angiotensin derivative or analog then V-L-R is other than a non-metal radionuclide substituted peptide (e.g. 125I substituted angiotensin II) and L-V is other than simply a peptide with a chelating agent amide bonded to a side chain thereof. This composition of matter may be used to image cardiovascular diseases and disorders.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: July 26, 2005
    Assignee: Amersham Health AS
    Inventors: Jo Klaveness, Anne Naevestad, Alan Cuthbertson
  • Patent number: 6676925
    Abstract: Detectably-labeled compounds of formula (I) wherein A,B,C,D,E,F,R,X,Y and Z have any of the meanings given in the specification, and their pharmaceutically acceptable salts, are useful in competitive assays to assay for the presence of 2 receptors. Also disclosed are pharmaceutical compositions containing such a compound of formula (I), methods for their use and intermediates useful for preparing such compounds of formula (I).
    Type: Grant
    Filed: March 20, 2000
    Date of Patent: January 13, 2004
    Assignee: Wake Forest University
    Inventors: Robert H. Mach, Kenneth T. Wheeler, Biao Yang, Steven R. Childers
  • Patent number: 6607710
    Abstract: An object of the present invention is to provide a bisphosphonic acid derivative and said bisphosphonic acid derivative being labeled with a radioactive nuclide, which has properties of rapid accumulation to the bone and rapid urinary excretion. The present invention relates to a bisphosphonic acid derivative and said bisphosphonic acid derivative being labeled with a radioactive nuclide, which is represented by the following general formula (1), R—Y—A  (1) wherein A is a bisphosphonic acid or a salt thereof, having P—C—P bond; Y is a bonding portion such as a methylene, an amido etc.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: August 19, 2003
    Assignee: Nihon Medi-Physics Co., Ltd.
    Inventors: Osamu Ito, Nobuhiko Kanazashi, Aki Morishita, Masamichi Hara, Masaru Kanagawa, Yasuko Watanabe, Yoshitoshi Itaya
  • Patent number: 6423322
    Abstract: Soft, creamy translucent and transparent gels suitable for use in cosmetic applications may be prepared by hydrosilylating an unsaturated MQ resin or its equivalent with an Si—H functional organopolysiloxane cross-linker having Si—H functionality along its polysiloxane backbone, in the presence of a low viscosity and preferably volatile organopolysiloxanes. The stable gels obtained may be converted to creamy gels of a wide range of consistency by simple shearing. Gel firmness can be maintained through addition of a catalyst inhibitor to the gel formulation.
    Type: Grant
    Filed: May 22, 1999
    Date of Patent: July 23, 2002
    Assignee: Wacker Silicones Corporation
    Inventor: Bryan E. Fry
  • Patent number: 6409987
    Abstract: A selectively targeted agent comprising a dermatan sulfate having more than about 25% repeating L-iduronic acid→4,6-di-O-sulfated N-acetyl-D-galactosamine disaccharide units that is covalently attached or bonded to a radioactive metal-ion binding moiety. The targeted agent is useful in preparing radiagnostic and/or radiopharmaceutical agents for diagnostic and/or therapeutic treatment when combined with an appropriate radioactive metal ion such as 99mTc, 186Re or 188Re.
    Type: Grant
    Filed: April 6, 2000
    Date of Patent: June 25, 2002
    Assignee: Intimax Corporation
    Inventors: Alan D. Cardin, Cornelius L. Van Gorp
  • Patent number: 6365128
    Abstract: A method of guiding the care of a critically ill patient or other high risk patient, said method comprising administering an effective dose of a gastric acid stimulant or suppressant agent and then measuring for an acute change in the gastric juice pH. A patient who demonstrates a significant change in the gastric juice pH using this test can have their medical care normalized in an accelerated fashion thereby reducing the duration, intensity, and cost of their care. Conversely, a patient who is not responsive is not ready for reduced support and may require more support.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: April 2, 2002
    Assignee: Medical Defence Technologies, LLC
    Inventors: Elliott Bennett-Guerrero, Michael G. Mythen
  • Patent number: 6348184
    Abstract: Novel radiopharmaceutical compositions comprising, in combination with a pharmaceutically acceptable carrier, a radioactive salt of pyrophosphoric acid. Also provided are novel radiopharmaceutical compositions comprising, in combination with one or more polymeric resins, a radioactive salt of pyrophosphoric acid. The compositions and matrices are suitable, inter alia, for use in treatment methods involving brachytherapy.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: February 19, 2002
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Jorge Osvaldo Nicolini, Ricardo Julio Ughetti
  • Patent number: 6346229
    Abstract: MR spectroscopy and imaging method for imaging pulmonary and cardiac vasculature and the cardiac region and evaluating blood flow or circulatory deficits use dissolved phase polarized 129Xe gas and large flip angle excitation pulses. Pulmonary and cardiac vasculature MRI images are obtained by delivering gas to a patient via inhalation such as with a breath-hold delivery-procedure, exciting the dissolved phase gas with a large flip angle pulse, and generating a corresponding image. Preferably, the image is obtained using multi-echo imaging techniques. Blood flow is quantified using low field MR spectroscopy and an RF excitation pulse with a frequency which corresponds to the resonance of the dissolved phase 129Xe.
    Type: Grant
    Filed: March 17, 1999
    Date of Patent: February 12, 2002
    Assignee: Medi-Physics, Inc.
    Inventors: Bastiaan Driehuys, Kenton Christopher Hasson, Paul Lev Bogorad
  • Patent number: 6342201
    Abstract: The present invention concerns novel complexes for use in the diagnosis of vascular diseases, methods of manufacturing such complexes and diagnostic agents containing them. These complexes strongly enrich themselves in atherosclerotic plaques and are thus suitable for use in non-invasive procedures for diagnosing atherosclerosis.
    Type: Grant
    Filed: July 17, 1997
    Date of Patent: January 29, 2002
    Assignee: Institut for Diagnostikforschung GmbH an der Freien Universitat
    Inventors: Ludger Dinkelborg, Christoph Stephan Hilger, Wolfhard Semmler, Ulrich Speck, Peter Henklein
  • Patent number: 6334996
    Abstract: The labeling of biologically important molecules via a bifunctional chelator can result in the formation of isomers or multiple species, which can have significant impact on the biological properties of the radiopharmaceutical. For receptor-based radiopharmaceuticals, the target uptake is largely dependent on the receptor binding affinity of the targeting molecule and the blood clearance of the labeled molecule, which is determined by the physical properties of both the targeting molecule and the metal chelate. Hence, the presence of isomers for the metal chelate can have significant impact on the radiopharmaceutical. Therefore, in the development of a radiopharmaceutical or metallodrug, it is necessary to separate the isomers and evaluate the biological activities of each individual isomer. It would therefore be desirable to develop chelators that predominately form only a single stereoisomeric species upon coordination to a metal center.
    Type: Grant
    Filed: December 24, 1997
    Date of Patent: January 1, 2002
    Assignee: Resolution Pharmaceuticals Inc.
    Inventor: Ernest Wong
  • Patent number: 6258338
    Abstract: A particulate material which comprises hollow or cup-shaped ceramic microspheres having a diameter in the range of from 5 to 200 microns. The material may comprise a beta- or gamma-emitting radionuclide and be used in selective internal radiation therapy (SIRT) of various forms of cancer and tumours.
    Type: Grant
    Filed: October 23, 1998
    Date of Patent: July 10, 2001
    Assignee: Sirtex Medical Limited
    Inventor: Bruce Nathaniel Gray
  • Patent number: 6248870
    Abstract: A method for diagnostic imaging a site in a patient. The method involves the use of an immunoreactive group which is linked to an unsymmetrical oligo-2,6-pyrimidine complexing agent.
    Type: Grant
    Filed: August 25, 1998
    Date of Patent: June 19, 2001
    Assignee: Nycomed Imaging AS
    Inventors: Daniel J. Delecki, Ashis Kumar Saha, Robert A. Snow
  • Patent number: 6241965
    Abstract: This invention relates to therapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labelled radiodiagnostic agents. Specifically, the invention relates to linear peptide derivatives and analogs of somatostatin, and embodiments of such peptides radiolabelled with a radioisotope, as well as methods and kits for making, radiolabelling and using such peptides for radiodiagnostic and radiotherapeutic purposes. The invention specifically relates to linear peptide derivatives and analogues of somatostatin radiolabelled with technetium-99m and uses thereof as scintigraphic imaging agents. The invention also specicically relates to linear peptide derivatives and analogues of somatostatin radiolabelled with cytotoxic radioisotopes such as rhenium-186 (186Re) and rhenium-188 (188Re) for use as radiotherapeutic agents. Methods and kits for making, radiolabelling and using such peptides diagnostically and therapeutically in a mammalian body are also provided.
    Type: Grant
    Filed: April 22, 1996
    Date of Patent: June 5, 2001
    Assignee: Diatide, Inc.
    Inventors: Richard T. Dean, William McBride
  • Patent number: RE39456
    Abstract: Disclosed are novel radioactive compositions which are particularly suited for treating solid mass tumors via catheter delivery.
    Type: Grant
    Filed: May 13, 2005
    Date of Patent: January 2, 2007
    Assignee: Micro Therapeutics, Inc.
    Inventors: Richard J. Greff, George Wallace